Key result
Oral flecainide at 200 mg or 300 mg daily did not significantly affect left ventricular ejection fraction after 7 days in patients with LV dysfunction.
Why the study?
Does oral flecainide reduce left ventricular ejection fraction in patients with left ventricular dysfunction?
Population
36 patients with left ventricular dysfunction (LVEF ≤40%)
Comparison
Oral flecainide 200 mg/day or 300 mg/day for 7… vs Baseline (prior to drug therapy)
Design
Cohort
Follow-up
7 days
Authors
Loading...
Short-term flecainide may be LVEF-neutral in LV dysfunction; leaves open risks in severe impairment (LVEF <30%).
Does oral flecainide reduce left ventricular ejection fraction in patients with left ventricular dysfunction?
p-value: p=NS
While oral flecainide does not significantly depress LVEF in patients with LV dysfunction, it is associated with severe cardiac adverse effects in those with severe impairment (LVEF <30%).
Brembilla-Perrot et al. (1987) studied Left ventricular dysfunction (n=36). Flecainide vs. Baseline was evaluated on Left ventricular ejection fraction (LVEF) (p=NS). Oral flecainide at 200 mg or 300 mg daily did not significantly affect left ventricular ejection fraction after 7 days in patients with LV dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: